Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Bradmer Pharmaceuticals Inc. (T.GLX) had Normalized Pre-Tax Income of -0.35M for the most recently reported fiscal quarter, ending 2018-03-31.
| Income Statement Financials | |
-- |
|
-0.35M |
|
-- |
|
-- |
|
-- |
|
-0.35M |
|
-- |
|
-0.35M |
|
|
Normalized Pre-Tax Income |
-0.35M |
-0.35M |
|
-0.35M |
|
-0.35M |
|
-0.35M |
|
-0.35M |
|
-0.35M |
|
0.16M |
|
0.16M |
|
-2.24 |
|
-2.24 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
0.34M |
|
-- |
|
-- |
|
-- |
|
0.41M |
|
-0.07M |
|
-0.07M |
|
-0.07M |
|
0.16M |
|
| Cash Flow Statement Financials | |
-0.07M |
|
-- |
|
-- |
|
0.40M |
|
0.34M |
|
-0.07M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.83 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-0.07M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
486.53% |
|
486.53% |
|
-100.58% |
|
486.53% |
|
-0.46 |
|
-0.44 |
|
-0.44 |
|